Three-month Variation of Plasma Pentraxin 3 Compared with C-reactive Protein, Albumin and Homocysteine Levels in Haemodialysis Patients

Overview

Journal Clin Kidney J

Publisher Oxford University Press

Specialty Nephrology

Date 2015 Apr 9

PMID 25852911

Citations 4

Authors

Bodil Sjoberg

Sunna Snaedal

Peter Stenvinkel

Abdul Rashid Qureshi

Olof Heimburger

Peter Barany

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory markers vary considerably over time in haemodialysis (HD) patients, yet the variability is poorly defined. The aim of the study was to assess changes of plasma levels of pentraxin-3 (PTX-3), C-reactive protein (CRP), albumin and homocysteine (Hcy) over 3 months and the association between the changes in these biomarkers and mortality.

Methods: In 188 prevalent HD patients, inflammatory markers were measured at inclusion and after 3 months. Mortality was recorded during a median follow-up of 41 months. The changes of the biomarker levels were categorized according to change in tertile for the specific biomarker. The variation was calculated as the intra-class correlation (ICC). Mortality was analysed by Kaplan-Meier and Cox proportional hazards model. The predictive strength was calculated for single measurements and for the variation of each inflammatory marker.

Results: The intra-individual variation (low ICC) was largest for PTX-3 [ICC 0.44; 95% confidence interval (CI): 0.33-0.55], albumin (ICC 0.58; 95% CI: 0.49-0.67) and CRP (ICC 0.59; 95% CI: 0.51-0.68) and lowest for Hcy (ICC 0.81; 95% CI: 0.77-0.86). During follow-up, 88 patients died.

Conclusions: PTX-3 measurements are less stable and show higher variation within patients than CRP, albumin and Hcy. Persistently elevated PTX-3 levels are associated with high mortality. Moreover, in multivariate logistic regression we found that stable high PTX-3 adds to the mortality risk, even after inclusion of clinical factors and the three other biomarkers. The associations of decreasing albumin levels as well as low Hcy levels with worse outcome reflect protein-energy wasting.

Citing Articles

Pentraxin-3 and Outcomes in CKD: A Systematic Review and Meta-analysis.

Li L, Liu H, Zhang Q, Jin H, Tao H, Chen H Kidney Med. 2024; 6(4):100800.

PMID: 38645733 PMC: 11026967. DOI: 10.1016/j.xkme.2024.100800.

Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies.

Trojnar E, Jozsi M, Szabo Z, Reti M, Farkas P, Kelen K Front Immunol. 2019; 10:240.

PMID: 30858847 PMC: 6397851. DOI: 10.3389/fimmu.2019.00240.

Pentraxins in the activation and regulation of innate immunity.

Daigo K, Inforzato A, Barajon I, Garlanda C, Bottazzi B, Meri S Immunol Rev. 2016; 274(1):202-217.

PMID: 27782337 PMC: 5412954. DOI: 10.1111/imr.12476.

Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly.

Sjoberg B, Qureshi A, Heimburger O, Stenvinkel P, Lind L, Larsson A J Intern Med. 2015; 279(2):173-9.

PMID: 26355706 PMC: 4737281. DOI: 10.1111/joim.12411.

References

deGoma E, French B, Dunbar R, Allison M, Mohler 3rd E, Budoff M . Intraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2012; 224(1):274-9. PMC: 4085141. DOI: 10.1016/j.atherosclerosis.2012.07.017. View

Qureshi A, Alvestrand A, Divino-Filho J, Gutierrez A, Heimburger O, Lindholm B . Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002; 13 Suppl 1:S28-36. View

Tong M, Carrero J, Qureshi A, Anderstam B, Heimburger O, Barany P . Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007; 2(5):889-97. DOI: 10.2215/CJN.00870207. View

Kaysen G, Dubin J, Muller H, Rosales L, Levin N, Mitch W . Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int. 2004; 65(4):1408-15. DOI: 10.1111/j.1523-1755.2004.00520.x. View

Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez De La Torre Y . The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006; 45(5):326-30. DOI: 10.1016/j.vph.2006.08.011. View

Witasp A, Ryden M, Carrero J, Qureshi A, Nordfors L, Naslund E . Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One. 2013; 8(5):e63493. PMC: 3643920. DOI: 10.1371/journal.pone.0063493. View

Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L . Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55(5):1899-911. DOI: 10.1046/j.1523-1755.1999.00422.x. View

Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F . PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000; 102(6):636-41. DOI: 10.1161/01.cir.102.6.636. View

Taskinen S, Hyvonen M, Kovanen P, Meri S, Pentikainen M . C-reactive protein binds to the 3beta-OH group of cholesterol in LDL particles. Biochem Biophys Res Commun. 2005; 329(4):1208-16. DOI: 10.1016/j.bbrc.2005.02.091. View

10.

Salio M, Chimenti S, de Angelis N, Molla F, Maina V, Nebuloni M . Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2008; 117(8):1055-64. DOI: 10.1161/CIRCULATIONAHA.107.749234. View

11.

Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, Moalli F . The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007; 204(4):793-804. PMC: 2118544. DOI: 10.1084/jem.20061301. View

12.

Klouche M, Peri G, Knabbe C, Eckstein H, Schmid F, Schmitz G . Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004; 175(2):221-8. DOI: 10.1016/j.atherosclerosis.2004.03.020. View

13.

Nascimento M, Pecoits-Filho R, Qureshi A, Hayashi S, Manfro R, Pachaly M . The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant. 2004; 19(11):2803-9. DOI: 10.1093/ndt/gfh493. View

14.

Imamura M, Kawasaki T, Savchenko A, Ohashi R, Jiang S, Miyamoto K . Lipopolysaccharide induced expression of pentraxin 3 in human neutrophils and monocyte-derived macrophages. Cell Immunol. 2007; 248(2):86-94. DOI: 10.1016/j.cellimm.2007.09.003. View

15.

Yilmaz M, Axelsson J, Sonmez A, Carrero J, Saglam M, Eyileten T . Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol. 2009; 4(3):535-41. PMC: 2653664. DOI: 10.2215/CJN.04330808. View

16.

Miyaki A, Maeda S, Otsuki T, Ajisaka R . Plasma pentraxin 3 concentration increases in endurance-trained men. Med Sci Sports Exerc. 2010; 43(1):12-7. DOI: 10.1249/MSS.0b013e3181e84bce. View

17.

Snaedal S, Heimburger O, Qureshi A, Danielsson A, Wikstrom B, Fellstrom B . Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis. 2009; 53(6):1024-33. DOI: 10.1053/j.ajkd.2009.02.008. View

18.

Ockene I, Matthews C, Rifai N, Ridker P, Reed G, Stanek E . Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001; 47(3):444-50. View

19.

Davies S, Phillips L, Naish P, Russell G . Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant. 2002; 17(6):1085-92. DOI: 10.1093/ndt/17.6.1085. View

20.

Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L . A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2007; 73(4):391-8. DOI: 10.1038/sj.ki.5002585. View